Results 211 to 220 of about 46,900 (298)

Randomised Controlled Multicentre Trial to Investigate the Effectiveness of a Mobile Artificial Intelligence Solution for Diabetes Adapted Care: The MELISSA Trial Protocol

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6576-6583, August 2026.
ABSTRACT Aims Achieving optimal glycaemic control remains a burden for many people with diabetes on intensive insulin treatment. The MELISSA trial aims to clinically validate the artificial intelligence (AI)‐based MELISSA system to support people with Type 1 diabetes on multiple daily insulin injections (MDI) with personalised insulin dose ...
Elisabeth J. den Brok, Cecilie H. Svensson, Mikkel T. Olsen, Nefeli M. Dimitropoulou, Sander M. J. van Kuijk, Maria Panagiotou, Lubnaa Abdur Rahman, Stephan Proennecke, Peter R. Mertens, Stavros Athanasopoulos, Cassy F. Dingena, Konstantinos Makrilakis, Stavroula Mougiakakou, Ulrik Pedersen‐Bjergaard, Bastiaan E. de Galan, on behalf of the MELISSA consortium   +15 more
wiley   +1 more source

Bullous Pemphigoid Secondary to Dipeptidyl Peptidase-4 (DPP4) Inhibitor: A Case Report. [PDF]

Cureus
Rosa R, Sousa Cardoso M, Pinheiro Silva I, Leal J, Torres B.   +4 more
europepmc   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6509-6532, August 2026.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano, Line L. Haurum, Christine R. Schwarz, Francesca Porcellati, Andreas Andersen   +4 more
wiley   +1 more source

Exertional heat stress and intestinal barrier injury: Does chronic disease add fuel to the fire?

Experimental Physiology, EarlyView.
Oliver R. Gibson, Zachary J. McKenna
wiley   +1 more source

Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus: A Cross‐Sectional Population‐Based Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7312-7320, August 2026.
ABSTRACT Aims Chronic kidney disease (CKD) is a common complication of Type 2 diabetes that frequently co‐occurs with cardiovascular disease. We aimed to characterise CKD in adults with Type 2 diabetes, quantify its prevalence across severity levels and examine pharmacological treatment patterns and healthcare utilisation.
Neora Alterman, Yoel Toledano, Noga Fallach, Victor Gross, Galia Zacay   +4 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitory Activity of Buckwheat Flour-Derived Peptides and Oral Glucose Tolerance Test of Buckwheat Flour Hydrolysates in Rats. [PDF]

Foods
Mitsui N, Shiono K, Seto Y, Furusho T, Saito C, Takahashi K.   +5 more
europepmc   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6874-6887, August 2026.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh, Brandon Michael Henry, István Édes   +2 more
wiley   +1 more source

A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor. [PDF]

Cureus
Fukata M, Omura T, Maeda K, Mori T, Kato H, Kuzuya M.   +5 more
europepmc   +1 more source

Patterns and Trends of Glucose‐Lowering Therapy in Alzheimer's Disease and Related Dementias

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7592-7596, August 2026.
Huilin Tang, Bingyu Zhang, Yiwen Lu, Ying Lu, Anastassia Amaro, Yuan Lu, David A. Wolk, Yong Chen   +7 more
wiley   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6533-6549, August 2026.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher   +4 more
wiley   +1 more source